PointState Capital’s Neurocrine Biosciences NBIX Stock Holding History

PointState Capital’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-6,600	Closed	-$581K	–	143
2019 Q1	$581K	Buy	+6,600	New	+$552K	0.01%	119
2018 Q3	–	Sell	-64,900	Closed	-$6.38M	–	169
2018 Q2	$6.38M	Buy	+64,900	New	+$5.81M	0.07%	118
2016 Q1	–	Sell	-525,000	Closed	-$29.7M	–	108
2015 Q4	$29.7M	Sell	525,000 -62,662	-11%	-$3.18M	0.75%	26
2015 Q3	$23.4M	Sell	587,662 -1,697,638	-74%	-$82.1M	0.65%	34
2015 Q2	$109M	Sell	2,285,300 -348,100	-13%	-$14.8M	1.28%	22
2015 Q1	$105M	Buy	2,633,400 +1,883,400	+251%	+$67.4M	1.41%	21
2014 Q4	$16.8M	Buy	+750,000	New	+$14.2M	0.29%	67
2013 Q4	–	Sell	-500,000	Closed	-$5.66M	–	166
2013 Q3	$5.66M	Sell	500,000 -625,000	-56%	-$8.59M	0.1%	97
2013 Q2	$15.1M	Buy	+1,125,000	New	+$13.8M	0.26%	75

Other funds holding NBIX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PointState Capital's NBIX Position: Q2 2019 in Review

PointState Capital sold out of Neurocrine Biosciences (NBIX) in Q2 2019, closing a stake of 6,600 shares — an estimated $581K sold.

PointState Capital first reported a position in NBIX in Q2 2013 and held it in 9 quarters. The position peaked at $109M in Q2 2015. 302 funds tracked by Wall St. Rank hold NBIX as of Q2 2019.

PointState Capital reported no remaining Neurocrine Biosciences position as of Q2 2019 after selling out during the quarter.
PointState Capital sold 6,600 Neurocrine Biosciences shares in Q2 2019, an estimated $581K.
PointState Capital first reported a position in Neurocrine Biosciences in Q2 2013 and held it in 9 quarters.
PointState Capital's Neurocrine Biosciences position peaked at $109M in Q2 2015.
302 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2019.

Based on PointState Capital's 13F filing for Q2 2019, filed 14 Aug 2019.